聚焦高质量发展｜看呼和浩特经开区如何跑出高质量发展“加速度”

Core Viewpoint - Hohhot Economic and Technological Development Zone is focusing on creating a first-class business environment, fostering an innovative ecosystem, and enhancing its capabilities to achieve high-quality development [1] Group 1: Business Environment Optimization - Hohhot Economic and Technological Development Zone has improved its business environment, allowing companies to enjoy convenient services such as full-process agency and "no-contact approval" [2] - The zone has transformed 3,582 public rental apartments into talent apartments to meet housing needs for employees of local enterprises, with 1,860 units already utilized by companies like Lile, Huayao Optoelectronics, and others [2] Group 2: Project Implementation and Investment - In 2023, the zone plans to implement 81 projects with a total investment of approximately 1.4 billion yuan, focusing on urban planning, transportation optimization, ecological restoration, and infrastructure improvement [3] - From January to May, the zone signed 32 investment agreements with a total investment of 20.98 billion yuan, with funds from outside the region reaching 2.005 billion yuan, a year-on-year increase of 75% [7] Group 3: Innovation Ecosystem Development - Technological innovation is the core driving force for the development of Hohhot Economic and Technological Development Zone, with several companies achieving significant milestones in the past year [4] - The zone has 7 leading technology enterprises and has nurtured 32 high-tech enterprises, with a national-level technology business incubator and innovation center under construction [5] Group 4: Industrial Upgrading and Modernization - The zone is transitioning from single manufacturing to a full value chain model of "R&D + manufacturing + services," exemplified by the establishment of the Intelligent Manufacturing Base for wind power equipment [6] - Hohhot Economic and Technological Development Zone is cultivating the biopharmaceutical industry as a pillar industry, with 22 biopharmaceutical companies, including 7 large-scale enterprises, forming a complete industrial chain [6]